The symptom network of lung cancer patients receiving taxane-based chemotherapy exhibits a tightly interconnected characteristic. Fatigue is the core hub symptom, and the frequency of chemotherapy-induced peripheral neuropathy is the key driver symptom. Additionally, the network structure shows age universality. Clinically, interventions can be prioritized for the aforementioned core symptoms to achieve efficient management of the overall symptom cluster.
Li et al. (Tue,) studied this question.